Genetic Technologies (GENE)
(Delayed Data from NSDQ)
$0.77 USD
-0.02 (-1.92%)
Updated Oct 16, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Genetic Technologies Ltd falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 5 | 9 | 16 | 10 |
Receivables | 1 | 1 | 2 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 2 | 7 | 11 | 17 | 10 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 2 | 4 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4 | 10 | 15 | 17 | 11 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 0 | 0 |
Total Current Liabilities | 3 | 2 | 3 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 2 | 3 | 1 | 2 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 113 | 0 | 0 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -109 | -106 | -109 | -107 | -91 |
Other Equity | 110 | 113 | 8 | 123 | 100 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1 | 8 | 12 | 16 | 9 |
Total Liabilities & Shareholder's Equity | 4 | 10 | 15 | 17 | 11 |
Total Common Equity | 1 | 8 | 12 | 16 | 9 |
Shares Outstanding | 4.80 | 3.80 | 3.00 | 3.00 | 2.70 |
Book Value Per Share | 0.25 | 1.98 | 3.97 | 5.36 | 3.24 |
Fiscal Year End for Genetic Technologies Ltd falls in the month of June.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | -99,999 | -99,997 | -99,999 |
Receivables | NA | 1 | NA | 1 | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | 0 | NA |
Other Current Assets | NA | 0 | NA | 0 | NA |
Total Current Assets | NA | 2 | NA | 4 | NA |
Net Property & Equipment | NA | 0 | NA | 0 | NA |
Investments & Advances | NA | 0 | NA | NA | NA |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | 0 | NA |
Intangibles | NA | 1 | NA | 1 | NA |
Deposits & Other Assets | NA | 0 | NA | 0 | NA |
Total Assets | NA | 4 | NA | 6 | NA |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 1 | NA | 1 | NA |
Current Portion Long-Term Debt | NA | 0 | NA | NA | NA |
Current Portion Capital Leases | NA | 0 | NA | 0 | NA |
Accrued Expenses | NA | 0 | NA | NA | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 1 | NA | 1 | NA |
Total Current Liabilities | NA | 3 | NA | 2 | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | 0 | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 0 | NA | NA | NA |
Non-Current Capital Leases | NA | 0 | NA | 0 | NA |
Other Non-Current Liabilities | NA | NA | 0 | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 3 | NA | 2 | NA |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 0 | NA | 105 | NA |
Capital Surplus | NA | 0 | NA | NA | NA |
Retained Earnings | NA | -109 | NA | -105 | NA |
Other Equity | NA | 110 | NA | 3 | NA |
Treasury Stock | NA | 0 | NA | NA | NA |
Total Shareholder's Equity | NA | 1 | NA | 3 | NA |
Total Liabilities & Shareholder's Equity | NA | 4 | NA | 6 | NA |
Total Common Equity | 0 | 1 | 0 | 100,002 | 0 |
Shares Outstanding | 4.80 | 4.80 | 4.40 | 3.80 | 3.80 |
Book Value Per Share | 0.00 | 0.25 | 0.00 | 26,316.35 | 0.00 |